dc.contributor.author |
Dilafruz Akhmedova, Mirkomil Tojiboyev, Munira Mahmudova |
|
dc.date.accessioned |
2022-10-10T17:08:30Z |
|
dc.date.available |
2022-10-10T17:08:30Z |
|
dc.date.issued |
2022 |
|
dc.identifier.uri |
http://repository.tma.uz/xmlui/handle/1/2857 |
|
dc.description.abstract |
To date, the treatment of OA is aimed primarily at the symptoms of the disease, i.e., to reduce pain and improve the functional state of the joints. The use of NSAIDs allows you to quickly reduce the intensity of pain and accelerate the recovery of motor activity in OA. However, the use of this group of drugs is associated with the development of adverse events in the gastrointestinal tract, cardiovascular system, kidneys and other organs, which is especially important in comorbid conditions in elderly patients. In this regard, it becomes clear that there is a high interest in the group of drugs with a delayed symptomatic effect, which have proven themselves excellently in arthrological practice |
en_US |
dc.language.iso |
other |
en_US |
dc.publisher |
Украина |
en_US |
dc.subject |
osteoarthrosis, chondroitin sulfate, glucosamine, methylsulfonylmethane |
en_US |
dc.title |
Modern approaches to the treatment of osteoarthrosis |
en_US |
dc.type |
Thesis |
en_US |